Dan Skovronsky knows what makes a good obesity medication.
As a scientific director at Eli LillyHe has already done it once with the weekly company of the company, Zepbound. He tries to start again with a more practical daily pill, then repeat the feat with a shot that could be even more powerful than Zepbound. And that does not count the other nine other drugs for Lilly tests in clinical trials.
Skovronsky said that the race to create the next main medicine is no longer concerned, which more investors and analysts are starting to say.
Take AmgenExperimental medication maritide: people have lost up to 20% of their body weight in a phase two study and AMGEN shares dropped by around 5% the day when the results were published in November. For what? Investors feared that it was not enough to compete with Wegovy from Lilly and Wegovy from Novo Nordisk, who will both have one step ahead.
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, in the United States on Thursday, March 28, 2024.
Shelby Knowles | Bloomberg | Getty images
Skovornsky is improving ease of use and making more powerful medications like two paths to advance the field. He envisages pills like Orforglipron de Lilly reaching people around the world. He sees drugs that can offer more weight loss – perhaps including Lilly’s own retruder – like another area with potential.
But it is the happiest to see how many other health conditions that incretinous – or the intestinal hormone – can treat. The Lilly Zepbound has recently been approved to treat sleep apnea. The company also explores if it can deal Debit, heart disease, inflammation and gastrointestinal conditions.
You can look at the full interview to find out more about Skovronsky on Lilly’s work in obesity and where he sees the market go.